[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ITRM20040105A1 - Anticorpo monoclonale antitenascina umana. - Google Patents

Anticorpo monoclonale antitenascina umana.

Info

Publication number
ITRM20040105A1
ITRM20040105A1 IT000105A ITRM20040105A ITRM20040105A1 IT RM20040105 A1 ITRM20040105 A1 IT RM20040105A1 IT 000105 A IT000105 A IT 000105A IT RM20040105 A ITRM20040105 A IT RM20040105A IT RM20040105 A1 ITRM20040105 A1 IT RM20040105A1
Authority
IT
Italy
Prior art keywords
pocket
human antibody
monoclonal anti
monoclonal
antibody
Prior art date
Application number
IT000105A
Other languages
English (en)
Inventor
Paolo Carminati
Santis Rita De
Giovanna Palombo
Angela Pelliccia
Original Assignee
Tecnogen Scpa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnogen Scpa filed Critical Tecnogen Scpa
Priority to IT000105A priority Critical patent/ITRM20040105A1/it
Publication of ITRM20040105A1 publication Critical patent/ITRM20040105A1/it
Priority to ES05718988.8T priority patent/ES2654065T3/es
Priority to CN2005800061324A priority patent/CN1946740B/zh
Priority to BRPI0508082A priority patent/BRPI0508082A8/pt
Priority to JP2007500356A priority patent/JP5191036B2/ja
Priority to CA2558718A priority patent/CA2558718C/en
Priority to PT57189888T priority patent/PT1718678T/pt
Priority to EP05718988.8A priority patent/EP1718678B1/en
Priority to PCT/IT2005/000078 priority patent/WO2005082938A2/en
Priority to PL05718988T priority patent/PL1718678T3/pl
Priority to MXPA06009674A priority patent/MXPA06009674A/es
Priority to AU2005217237A priority patent/AU2005217237B2/en
Priority to US10/590,936 priority patent/US7989171B2/en
Priority to ARP050100671A priority patent/AR047819A1/es
Priority to KR1020067020062A priority patent/KR101266389B1/ko
Priority to HK07108522.3A priority patent/HK1100848A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IT000105A 2004-02-27 2004-02-27 Anticorpo monoclonale antitenascina umana. ITRM20040105A1 (it)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IT000105A ITRM20040105A1 (it) 2004-02-27 2004-02-27 Anticorpo monoclonale antitenascina umana.
US10/590,936 US7989171B2 (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody
PT57189888T PT1718678T (pt) 2004-02-27 2005-02-16 Anticorpo monoclonal de tenascina anti-humano
PCT/IT2005/000078 WO2005082938A2 (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody
BRPI0508082A BRPI0508082A8 (pt) 2004-02-27 2005-02-16 Anticorpo monoclonal de tenascina antihumano
JP2007500356A JP5191036B2 (ja) 2004-02-27 2005-02-16 抗ヒトテネイシンモノクローナル抗体
CA2558718A CA2558718C (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody
ES05718988.8T ES2654065T3 (es) 2004-02-27 2005-02-16 Anticuerpo monoclonal anti-tenascina humana
EP05718988.8A EP1718678B1 (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody
CN2005800061324A CN1946740B (zh) 2004-02-27 2005-02-16 抗人腱生蛋白单克隆抗体
PL05718988T PL1718678T3 (pl) 2004-02-27 2005-02-16 Przeciwciało monoklonalne przeciw ludzkiej tenascynie
MXPA06009674A MXPA06009674A (es) 2004-02-27 2005-02-16 Anticuerpo monoclonal de tenascina antihumano.
AU2005217237A AU2005217237B2 (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody
ARP050100671A AR047819A1 (es) 2004-02-27 2005-02-24 Un anticuerpo monoclonal anti-tenascina humana
KR1020067020062A KR101266389B1 (ko) 2004-02-27 2006-09-27 항 인간 테나신 단클론 항체
HK07108522.3A HK1100848A1 (en) 2004-02-27 2007-08-06 Anti-human tenascin monoclonal antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000105A ITRM20040105A1 (it) 2004-02-27 2004-02-27 Anticorpo monoclonale antitenascina umana.

Publications (1)

Publication Number Publication Date
ITRM20040105A1 true ITRM20040105A1 (it) 2004-05-27

Family

ID=34897820

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000105A ITRM20040105A1 (it) 2004-02-27 2004-02-27 Anticorpo monoclonale antitenascina umana.

Country Status (16)

Country Link
US (1) US7989171B2 (it)
EP (1) EP1718678B1 (it)
JP (1) JP5191036B2 (it)
KR (1) KR101266389B1 (it)
CN (1) CN1946740B (it)
AR (1) AR047819A1 (it)
AU (1) AU2005217237B2 (it)
BR (1) BRPI0508082A8 (it)
CA (1) CA2558718C (it)
ES (1) ES2654065T3 (it)
HK (1) HK1100848A1 (it)
IT (1) ITRM20040105A1 (it)
MX (1) MXPA06009674A (it)
PL (1) PL1718678T3 (it)
PT (1) PT1718678T (it)
WO (1) WO2005082938A2 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561361A (en) 2005-02-11 2010-02-26 Amylin Pharmaceuticals Inc GIP hybrid polypeptides with at least two hormonal activities
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2012031084A (ja) * 2010-07-29 2012-02-16 Tokyo Univ Of Science 抗腫瘍剤
WO2014113459A1 (en) * 2013-01-15 2014-07-24 Duke University Hiv-1 neutralizing factor
US20160097771A1 (en) * 2013-05-21 2016-04-07 NX Pharmagen Use of tenascin-c as an extracellular marker of tumor-derived microparticles
GB201616596D0 (en) * 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5634076A (en) * 1994-10-04 1997-05-27 Analog Devices, Inc. DMA controller responsive to transition of a request signal between first state and second state and maintaining of second state for controlling data transfer
US6014709A (en) * 1997-11-05 2000-01-11 Unisys Corporation Message flow protocol for avoiding deadlocks
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
JP2003512300A (ja) * 1999-05-01 2003-04-02 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー テネイシンｃによる軸索突起の伸長及び誘導
US7058750B1 (en) * 2000-05-10 2006-06-06 Intel Corporation Scalable distributed memory and I/O multiprocessor system
JP3646159B2 (ja) * 2001-02-08 2005-05-11 国立大学法人三重大学 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ
ITRM20010079A1 (it) * 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
US7438908B2 (en) * 2002-02-26 2008-10-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-human tenascin monoclonal antibody
ITRM20020128A1 (it) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
KR101266389B1 (ko) 2013-05-28
BRPI0508082A (pt) 2007-07-17
WO2005082938A2 (en) 2005-09-09
JP5191036B2 (ja) 2013-04-24
AU2005217237B2 (en) 2011-12-22
AU2005217237A1 (en) 2005-09-09
KR20070002029A (ko) 2007-01-04
CA2558718A1 (en) 2005-09-09
HK1100848A1 (en) 2007-09-28
PT1718678T (pt) 2017-12-29
US20100297003A1 (en) 2010-11-25
ES2654065T3 (es) 2018-02-12
CN1946740A (zh) 2007-04-11
BRPI0508082A8 (pt) 2017-12-26
US7989171B2 (en) 2011-08-02
CA2558718C (en) 2015-01-13
EP1718678A2 (en) 2006-11-08
JP2008506355A (ja) 2008-03-06
CN1946740B (zh) 2012-09-05
MXPA06009674A (es) 2007-03-21
WO2005082938A3 (en) 2005-12-15
EP1718678B1 (en) 2017-10-11
PL1718678T3 (pl) 2018-05-30
AR047819A1 (es) 2006-02-22

Similar Documents

Publication Publication Date Title
LTPA2018515I1 (lt) Antagonistiniai IL-17 antikūnai
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
NO20071430L (no) Anti-OX4OL antistoffer
CY2016030I1 (el) Αντισωματα εναντι της il-17
NO20071069L (no) Anti-CD154-antistoff
DK1771482T3 (da) HER2-antistofsammensætning
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
DK1599504T3 (da) Modificeret antistof
DE602006017373D1 (de) Madcam-antikörper
DK3656793T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK1964852T3 (da) Anti-ilt7-antistof
NO20076607L (no) TWEAK - bindende antistoff
MA28726B1 (fr) Immunoglobulines
MA28541B1 (fr) Immunoglobulines
DK2292663T3 (da) Antagonistiske human-let-specifikke, humane monoklonale antistoffer
SG10201404801YA (en) Monoclonal antibody
NL1028967A1 (nl) 4-Fenylamino-chinazoline-6-yl-amiden.
NO20041374L (no) Bolgekraftverk.
BRPI0509495A2 (pt) anticorpo humanizado
DK1809660T3 (da) Thymus-specifikt protein
ITRM20040105A1 (it) Anticorpo monoclonale antitenascina umana.
EP1712564A4 (en) MONOCLONAL ANTIBODY ANTI-NC1
ES1057731Y (es) Cortauñas.
GB0415644D0 (en) Monoclonal antibody
ES1058397Y (es) Arqueta prefabricada.